Ionis Pharmaceuticals Inc. [NASDAQ: IONS] slipped around -2.56 points on Thursday, while shares priced at $37.33 at the close of the session, down -6.42%. The company report on May 6, 2021 that Ionis to present at upcoming investor conferences.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that management will participate in virtual fireside chats at the following investor conferences:.
Bank of America Healthcare Conference on Wednesday, May 12, 2021.
Ionis Pharmaceuticals Inc. stock is now -33.98% down from its year-to-date (YTD) trading value. IONS Stock saw the intraday high of $39.58 and lowest of $36.03 per share. The company’s 52-week high price is 64.37, which means current price is +3.61% above from all time high which was touched on 01/26/21.
Compared to the average trading volume of 1.39M shares, IONS reached a trading volume of 4029473 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Ionis Pharmaceuticals Inc. [IONS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IONS shares is $58.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IONS stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Ionis Pharmaceuticals Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on March 01, 2021. While these analysts kept the previous recommendation, UBS raised their target price to Sell. The new note on the price target was released on December 16, 2020, representing the official price target for Ionis Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Ionis Pharmaceuticals Inc. is set at 1.84, with the Price to Sales ratio for IONS stock in the period of the last 12 months amounting to 7.30. The Price to Book ratio for the last quarter was 6.19, with the Price to Cash per share for the same quarter was set at 13.27. Price to Free Cash Flow for IONS in the course of the last twelve months was 6653.14 with Quick ratio for the last quarter at 3.60.
How has IONS stock performed recently?
Ionis Pharmaceuticals Inc. [IONS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.83. With this latest performance, IONS shares dropped by -14.48% in over the last four-week period, additionally sinking by -20.57% over the last 6 months – not to mention a drop of -33.94% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IONS stock in for the last two-week period is set at 27.49, with the RSI for the last a single of trading hit 20.90, and the three-weeks RSI is set at 31.38 for Ionis Pharmaceuticals Inc. [IONS]. The present Moving Average for the last 50 days of trading for this stock 46.51, while it was recorded at 41.00 for the last single week of trading, and 51.73 for the last 200 days.
Ionis Pharmaceuticals Inc. [IONS]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Ionis Pharmaceuticals Inc. [IONS] shares currently have an operating margin of -23.60 and a Gross Margin at +96.01. Ionis Pharmaceuticals Inc.’s Net Margin is presently recorded at -61.91.
Return on Total Capital for IONS is now -7.71, given the latest momentum, and Return on Invested Capital for the company is -22.87. Return on Equity for this stock declined to -39.01, with Return on Assets sitting at -16.06. When it comes to the capital structure of this company, Ionis Pharmaceuticals Inc. [IONS] has a Total Debt to Total Equity ratio set at 136.13. Additionally, IONS Total Debt to Total Capital is recorded at 57.65, with Total Debt to Total Assets ending up at 48.04. Long-Term Debt to Equity for the company is recorded at 100.51, with the Long-Term Debt to Total Capital now at 42.56.
Reflecting on the efficiency of the workforce at the company, Ionis Pharmaceuticals Inc. [IONS] managed to generate an average of -$596,416 per employee. Receivables Turnover for the company is 10.48 with a Total Asset Turnover recorded at a value of 0.26.Ionis Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.60 and a Current Ratio set at 3.70.
Earnings analysis for Ionis Pharmaceuticals Inc. [IONS]
With the latest financial reports released by the company, Ionis Pharmaceuticals Inc. posted -0.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 14.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IONS.
Insider trade positions for Ionis Pharmaceuticals Inc. [IONS]
There are presently around $4,803 million, or 87.40% of IONS stock, in the hands of institutional investors. The top three institutional holders of IONS stocks are: FMR LLC with ownership of 20,938,034, which is approximately 0.341% of the company’s market cap and around 0.20% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 13,114,967 shares of the stock with an approximate value of $523.16 million in IONS stocks shares; and VANGUARD GROUP INC, currently with $488.43 million in IONS stock with ownership of nearly 2.121% of the company’s market capitalization.
Positions in Ionis Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 186 institutional holders increased their position in Ionis Pharmaceuticals Inc. [NASDAQ:IONS] by around 15,071,180 shares. Additionally, 164 investors decreased positions by around 8,633,752 shares, while 76 investors held positions by with 96,697,228 shares. The mentioned changes placed institutional holdings at 120,402,160 shares, according to the latest SEC report filing. IONS stock had 53 new institutional investments in for a total of 2,628,360 shares, while 53 institutional investors sold positions of 1,825,596 shares during the same period.